Isoprostanes as a biomarker of lipid peroxidation in humans: Physiology, pharmacology and clinical implications

Trends in Pharmacological Sciences

Volumn 23, Issue 8, 2002, Pages 360-366

  Cracowski, Jean Luc ^a   Durand, Thierry ^b   Bessard, Germain ^a  

^a UNIV GRENOBLE ALPES   (France)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; BIOLOGICAL MARKER; ISOPROSTANE DERIVATIVE; PROSTANOID RECEPTOR;

ATHEROSCLEROSIS; BRONCHOSPASM; CATALYSIS; CATALYST; DISEASE ASSOCIATION; HUMAN; INFLAMMATION; ISCHEMIA; LIPID PEROXIDATION; NOCICEPTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; RELIABILITY; REPERFUSION; REVIEW; VASOCONSTRICTION;

EID: 0036697124     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(02)02053-9     Document Type: Review

References (72)

1. Nugteren D.H., et al. Non-enzymatic conversion of all-cis 8,11,14-eicosatrienoic acid into prostaglandin E1. Rec. Trav. Chim. 86:1967;1237-1245.
2. Pryor W.A., et al. Autoxidation of polyunsaturated fatty acids: II. A suggested mechanism for the formation of TBA-reactive materials from prostaglandin-like endoperoxides. Lipids. 11:1976;370-379.
3. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. U. S. A. 87:1990;9383-9387.
4. 3-isoprostanes during peroxidation of eicosapentaenoic acid. Biochem. Biophys. Res. Commun. 236:1997;467-472.
5. Roberts L.J. 2nd, et al. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J. Biol. Chem. 273:1998;13605-13612.
6. 4-isoprostanes: a novel class of prostanoids formed during peroxidation of docosahexaenoic acid (DHA). Biochem. Biophys. Res. Commun. 242:1998;338-344.
7. 2-isoprostanes as an index of oxidative stress in vivo. Free Radic. Biol. Med. 28:2000;505-513.
8. Tsikas D. Application of gas chromatography-mass spectrometry and gas chromatography-tandem mass spectrometry to assess in vivo synthesis of prostaglandins, thromboxane, leukotrienes, isoprostanes and related compounds in humans. J. Chromatogr. B Biomed. Sci. Appl. 717:1998;201-245.
9. Lawson J.A., et al. Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J. Biol. Chem. 274:1999;24441-24444.
10. Janssen L.J. Isoprostanes: an overview and putative roles in pulmonary pathophysiology. Am. J. Physiol. Lung Cell. Mol. Physiol. 280:2001;L1067-1082.
11. Cracowski J.L., et al. Vascular biology of the isoprostanes. J. Vasc. Res. 38:2001;93-103.
12. Cranshaw J.H., et al. Characterization of the effects of isoprostanes on platelet aggregation in human whole blood. Br. J. Pharmacol. 132:2001;1699-1706.
13. 2-isoprostanes possess no vasomotor effects in the rat thoracic aorta, the human internal mammary artery and the human saphenous vein. Br. J. Pharmacol. 135:2002;1276-1280.
14. Janssen L.J. Are endothelium-derived hyperpolarizing and contracting factors isoprostanes? Trends Pharmacol. Sci. 23:2002;59-62.
15. 2α in humans. J. Biol. Chem. 271:1996;20617-20620.
16. 2α. J. Biol. Chem. 274:1999;1313-1319.
17. 2α. FEBS Lett. 428:1998;32-36.
18. 2t-isoprostane: a bioactive prostanoid metabolite. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281:2001;R391-400.
19. 2-isoprostane metabolites. J. Cardiovasc. Pharmacol. 39:2002;396-403.
20. 2-isoprostane formation: evidence for in vivo oxidative stress during PTCA. J. Am. Coll. Cardiol. 37:2001;76-80.
21. 2α. Br. J. Pharmacol. 119:1996;1276-1280.
22. 2-isoprostane formation in vascular diseases. J. Am. Coll. Cardiol. 39:2002;554-555.
23. 2-isoprostane regioisomers formed in vivo in the rat. Free Radic. Biol. Med. 23:1997;943-954.
24. 2α-VI, in human urine. J. Biol. Chem. 273:1998;29295-29301.
25. 2α in human urine. J. Chromatogr. B Biomed. Sci. Appl. 744:2000;99-112.
26. 2α-I: an index of lipid peroxidation in humans. Proc. Natl. Acad. Sci. U. S. A. 95:1998;3449-3454.
27. 2α excretion in man. J. Pharmacol. Exp. Ther. 275:1995;94-100.
28. 2α in human plasma and urine by liquid chromatography-electrospray ionization mass spectrometry. J. Chromatogr. B Biomed. Sci. Appl. 746:2000;17-24.
29. Richelle M., et al. Urinary isoprostane excretion is not confounded by the lipid content of the diet. FEBS Lett. 459:1999;259-262.
30. Ide T., et al. Greater oxidative stress in healthy young men compared with premenopausal women. Arterioscler. Thromb. Vasc. Biol. 22:2002;438-452.
31. 2-isoprostane excretion in migraine. Clin. Sci. 102:2002;39-43.
32. 2-isoprostane excretion rate and diurnal variation in human urine. Prostaglandins Leukot. Essent. Fatty Acids. 61:1999;203-205.
33. 2α, a novel index of lipid peroxidation in vivo, by immunoaffinity extraction/gas chromatography-mass spectrometry. Basal levels in smokers and nonsmokers. Free Radic. Biol. Med. 20:1996;619-624.
34. Reilly M., et al. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation. 94:1996;19-25.
35. Cracowski J.L., et al. Increased lipid peroxidation in patients with pulmonary hypertension. Am. J. Respir. Crit. Care Med. 164:2001;1038-1042.
36. Meagher E.A., et al. Alcohol-induced generation of lipid peroxidation products in humans. J. Clin. Invest. 104:1999;805-813.
37. Obata T., et al. Smoking and oxidant stress: assay of isoprostane in human urine by gas chromatography-mass spectrometry. J. Chromatogr. B Biomed. Sci. Appl. 746:2000;11-15.
38. 2α, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer's disease. Free Radic. Biol. Med. 27:1999;463-469.
39. 2-isoprostanes unveils profound oxidative stress in aged rats. Biochem. Biophys. Res. Commun. 287:2001;254-256.
40. 2-isoprostane levels. Free Radic. Biol. Med. 28:2000;806-814.
41. Hinchcliff K.W., et al. Oxidant stress in sled dogs subjected to repetitive endurance exercise. Am. J. Vet. Res. 61:2000;512-517.
42. Kirschvink, N. et al. Effect of chronic airway inflammation and exercise on pulmonary and systemic antioxidant status of healthy and heaves-affected horses. Equine Vet. J. (in press)
43. 2-isoprostane excretion in non-insulin-dependent diabetic patients. Metabolism. 48:1999;1402-1408.
44. Childs A., et al. Supplementation with vitamin C and N-acetyl-cysteine increases oxidative stress in humans after an acute muscle injury induced by eccentric exercise. Free Radic. Biol. Med. 31:2001;745-753.
45. Mastaloudis A., et al. Oxidative stress in athletes during extreme endurance exercise. Free Radic. Biol. Med. 31:2001;911-922.
46. 2-isoprostanes) in smokers. New Engl. J. Med. 332:1995;1198-1203.
47. Sinzinger H. Eicosanoid production and lymphatic responsiveness in human cigarette smokers compared with non-smokers. Lymphology. 33:2000;24-31.
48. Montuschi P., et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am. J. Respir. Crit. Care Med. 162:2000;1175-1177.
49. Oguogho A., et al. Isoprostanes quickly normalize after quitting cigarette smoking in healthy adults. Vasa. 29:2000;103-105.
50. 2α after restarting smoking. Prostaglandins Leukot. Essent. Fatty Acids. 64:2001;307-310.
51. 2-isoprostanes and reduces prostacyclin and nitric oxide in umbilical vessels. Prostaglandins Other Lipid Mediat. 57:1999;269-279.
52. 2-isoprostanes in patients with Crohn's disease. Am. J. Gastroenterol. 97:2002;99-103.
53. Montuschi P., et al. Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients. Am. J. Respir. Crit. Care Med. 160:1999;216-220.
54. Wood L.G., et al. Lipid peroxidation as determined by plasma isoprostanes is related to disease severity in mild asthma. Lipids. 35:2000;967-974.
55. Pratico D., et al. Enhanced lipid peroxidation in hepatic cirrhosis. J. Investig. Med. 46:1998;51-57.
56. Cracowski J.L., et al. Enhanced in vivo lipid peroxidation in scleroderma spectrum disorders. Arthritis Rheum. 44:2001;1143-1148.
57. 2α and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation. 99:1999;224-229.
58. 2-isoprostane excretion in alcoholic liver disease. Free Radic. Biol. Med. 26:1999;656-660.
59. 2α-III, an index of oxidant stress. Am. J. Respir. Crit. Care Med. 158:1998;1709-1714.
60. 2α in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation. 97:1998;1536-1539.
61. Ciabattoni G., et al. In vivo lipid peroxidation and platelet activation in cystic fibrosis. Am. J. Respir. Crit. Care Med. 162:2000;1195-1201.
62. Davi G., et al. Oxidative stress and platelet activation in homozygous homocystinuria. Circulation. 104:2001;1124-1128.
63. 2α is increased in hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 17:1997;3230-3235.
64. Ferro D., et al. Vitamin E reduces monocyte tissue factor expression in cirrhotic patients. Blood. 93:1999;2945-2950.
65. 2-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. Circulation. 102:2000;539-545.
66. Meagher E.A., et al. Effects of vitamin E on lipid peroxidation in healthy persons. J. Am. Med. Assoc. 285:2001;1178-1182.
67. Weinberg R.B., et al. Pro-oxidant effect of vitamin E in cigarette smokers consuming a high polyunsaturated fat diet. Arterioscler. Thromb. Vasc. Biol. 21:2001;1029-1033.
68. Chowienczyk P.J., et al. Oral treatment with an antioxidant (raxofelast) reduces oxidative stress and improves endothelial function in men with type II diabetes. Diabetologia. 43:2000;974-977.
69. Levine M., et al. A new recommended dietary allowance of vitamin C for healthy young women. Proc. Natl. Acad. Sci. U. S. A. 98:2001;9842-9846.
70. 2- isoprostanes. Am. J. Clin. Nutr. 72:2000;714-722.
71. Visioli F., et al. Olive oils rich in natural catecholic phenols decrease isoprostane excretion in humans. Biochem. Biophys. Res. Commun. 278:2000;797-799.
72. 2-isoprostane concentrations and increase resistance of low-density lipoprotein to oxidation in humans. Am. J. Clin. Nutr. 72:2000;395-400.